Umbralisib用于BTK或PI3Kδ抑制剂不耐受CLL患者的II期研究
患者接受umbralisib 800 mg/d治疗,中位无进展生存期为23.5个月(95%CI 13.1-不可估计),58%的患者用药时间长于先前激酶抑制剂,最常见≥3级不良事件为中性粒细胞减少(18%)。这是首个前瞻性数据,证实对此类不耐受患者换用umbralisib可获得持久且耐受良好的缓解。
要点
- Umbralisib在BTK/PI3K抑制剂不耐受的CLL患者中中位PFS达23.5个月
- 58%患者使用umbralisib时间长于先前激酶抑制剂
- 仅12%患者因不良事件停用umbralisib,16%经剂量调整后成功再挑战
核心结论
- 在BTK抑制剂和PI3K抑制剂不耐受的CLL患者中,换用umbralisib可产生持久且耐受良好的缓解。
研究设计与样本
- Umbralisib起始剂量800 mg/d,持续至疾病进展或毒性;主要终点为无进展生存期(PFS)。
- 中位年龄70岁(范围48-96),中位既往治疗线数2(范围1-7),24%有del17p和/或TP53突变,65%为IGHV未突变。
主要发现
- 中位PFS为23.5个月(95%CI 13.1-不可估计)。
- 58%的患者使用umbralisib的时间长于先前激酶抑制剂。
- 导致先前激酶抑制剂停用的最常见不良事件为皮疹(27%)、关节痛(18%)和房颤(16%)。
- Umbralisib最常见(≥5%)的≥3级不良事件(所有因果关系)为中性粒细胞减少(18%)、白细胞增多(14%)、血小板减少(12%)、肺炎(12%)和腹泻(8%)。
- 6例(12%)因不良事件停用umbralisib,8例(16%)进行剂量调整并成功再挑战。
临床怎么用
- 对于BTK抑制剂或PI3K抑制剂不耐受的CLL患者,可考虑换用umbralisib治疗。
- 治疗期间需监测中性粒细胞减少、白细胞增多、血小板减少、肺炎和腹泻等不良事件。
- 部分患者可通过剂量调整后成功再挑战umbralisib。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intolerance is the most common reason for kinase inhibitor (KI) discontinuation in chronic lymphocytic leukemia (CLL). Umbralisib, a novel highly selective phosphatidylinositol 3-kinase δ (PI3Kδ)/CK1ε inhibitor, is active and well tolerated in CLL patients. In this phase 2 trial (NCT02742090), umbralisib was initiated at 800 mg/d in CLL patients requiring therapy, who were intolerant to prior BTK inhibitor (BTKi) or PI3K inhibitor (PI3Ki) therapy, until progression or toxicity. Primary end point was progression-free survival (PFS). Secondary end points included time to treatment failure and safety. DNA was genotyped for CYP3A4, CYP3A5, and CYP2D6 polymorphisms. Fifty-one patients were enrolled (44 BTKi intolerant and 7 PI3Kδi intolerant); median age was 70 years (range, 48-96), with a median of 2 prior lines of therapy (range, 1-7), 24% had del17p and/or TP53 mutation, and 65% had unmutated IGHV. Most common adverse events (AEs) leading to prior KI discontinuation were rash (27%), arthralgia (18%), and atrial fibrillation (16%). Median PFS was 23.5 months (95% CI, 13.1-not estimable), with 58% of patients on umbralisib for a longer duration than prior KI. Most common (≥5%) grade ≥3 AEs on umbralisib (all causality) were neutropenia (18%), leukocytosis (14%), thrombocytopenia (12%), pneumonia (12%), and diarrhea (8%). Six patients (12%) discontinued umbralisib because of an AE. Eight patients (16%) had dose reductions and were successfully rechallenged. These are the first prospective data to confirm that switching from a BTKi or alternate PI3Ki to umbralisib in this BTKi- and PI3Ki-intolerant CLL population can result in durable well-tolerated responses.
引用
- Mato AR, Ghosh N, Schuster SJ, et al. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. Blood. 2021. PMID: 33259589. doi:10.1182/blood.2020007376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。